Medizinische Klinik und Poliklinik 1, Universitätsklinikum Carl Gustav Carus, Dresden, Germany.
Medizinische Klinik 3, Klinikum Leverkusen, Leverkusen, Germany.
Blood Cancer J. 2023 May 26;13(1):88. doi: 10.1038/s41408-023-00858-y.
Tandem-duplication mutations of the UBTF gene (UBTF-TDs) coding for the upstream binding transcription factor have recently been described in pediatric patients with acute myeloid leukemia (AML) and were found to be associated with particular genetics (trisomy 8 (+8), FLT3-internal tandem duplications (FLT3-ITD), WT1-mutations) and inferior outcome. Due to limited knowledge on UBTF-TDs in adult AML, we screened 4247 newly diagnosed adult AML and higher-risk myelodysplastic syndrome (MDS) patients using high-resolution fragment analysis. UBTF-TDs were overall rare (n = 52/4247; 1.2%), but significantly enriched in younger patients (median age 41 years) and associated with MDS-related morphology as well as significantly lower hemoglobin and platelet levels. Patients with UBTF-TDs had significantly higher rates of +8 (34% vs. 9%), WT1 (52% vs. 7%) and FLT3-ITD (50% vs. 20.8%) co-mutations, whereas UBTF-TDs were mutually exclusive with several class-defining lesions such as mutant NPM1, in-frame CEBPA mutations as well as t(8;21). Based on the high-variant allele frequency found and the fact that all relapsed patients analyzed (n = 5) retained the UBTF-TD mutation, UBTF-TDs represent early clonal events and are stable over the disease course. In univariate analysis, UBTF-TDs did not represent a significant factor for overall or relapse-free survival in the entire cohort. However, in patients under 50 years of age, who represent the majority of UBTF-mutant patients, UBTF-TDs were an independent prognostic factor for inferior event-free (EFS), relapse-free (RFS) and overall survival (OS), which was confirmed by multivariable analyses including established risk factors such as age and ELN2022 genetic risk groups (EFS [HR: 2.20; 95% CI 1.52-3.17, p < 0.001], RFS [HR: 1.59; 95% CI 1.02-2.46, p = 0.039] and OS [HR: 1.64; 95% CI 1.08-2.49, p = 0.020]). In summary, UBTF-TDs appear to represent a novel class-defining lesion not only in pediatric AML but also younger adults and are associated with myelodysplasia and inferior outcome in these patients.
串联重复突变的 UBTF 基因(UBTF-TDs)编码上游结合转录因子,最近在儿科急性髓系白血病(AML)患者中被描述,并与特定的遗传学(三体 8(+8)、FLT3 内串联重复(FLT3-ITD)、WT1 突变)和不良预后相关。由于成人 AML 中 UBTF-TDs 的知识有限,我们使用高分辨率片段分析筛选了 4247 例新诊断的成人 AML 和高危骨髓增生异常综合征(MDS)患者。UBTF-TDs 总体上很少见(n=52/4247;1.2%),但在年轻患者中明显富集(中位年龄 41 岁),与 MDS 相关的形态学以及显著降低的血红蛋白和血小板水平相关。携带 UBTF-TDs 的患者 +8 的发生率显著升高(34% vs. 9%)、WT1(52% vs. 7%)和 FLT3-ITD(50% vs. 20.8%)的共突变率也显著升高,而 UBTF-TDs 与多个定义类别病变是相互排斥的,如突变型 NPM1、框内 CEBPA 突变和 t(8;21)。基于发现的高变异等位基因频率以及分析的所有复发患者(n=5)均保留 UBTF-TD 突变的事实,UBTF-TDs 代表早期克隆事件,并且在疾病过程中稳定。在单变量分析中,UBTF-TDs 在整个队列的总生存期或无复发生存期方面均不是一个显著因素。然而,在年龄在 50 岁以下的患者中,他们代表了大多数 UBTF 突变患者,UBTF-TDs 是无事件生存(EFS)、无复发生存(RFS)和总生存(OS)的独立预后因素,这在包括年龄和 ELN2022 遗传风险组等既定风险因素在内的多变量分析中得到了证实(EFS [HR:2.20;95%CI 1.52-3.17,p<0.001]、RFS [HR:1.59;95%CI 1.02-2.46,p=0.039] 和 OS [HR:1.64;95%CI 1.08-2.49,p=0.020])。总之,UBTF-TDs 似乎不仅在儿科 AML 中,而且在年轻成年人中也代表了一种新的定义类别病变,并且与这些患者的骨髓增生异常和不良预后相关。